Schroder Investment Management Group’s Xenon Pharmaceuticals XENE Stock Holding History

Schroder Investment Management Group’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.32M	Buy	121,819 +40,663	+50%	+$2.26M	0.01%	723
2026 Q1	$4.51M	Hold	81,156	–	–	﹤0.01%	796
2025 Q4	$3.58M	Hold	81,156	–	–	﹤0.01%	806
2025 Q3	$3.17M	Sell	81,156 -47,947	-37%	-$1.69M	﹤0.01%	850
2025 Q2	$4.04M	Sell	129,103 -8,118	-6%	-$265K	﹤0.01%	806
2025 Q1	$4.7M	Sell	137,221 -39,453	-22%	-$1.5M	﹤0.01%	765
2024 Q4	$6.81M	Hold	176,674	–	–	0.01%	718
2024 Q3	$6.83M	Buy	176,674 +85,174	+93%	+$3.43M	0.01%	737
2024 Q2	$3.57M	Hold	91,500	–	–	﹤0.01%	839
2024 Q1	$3.94M	Hold	91,500	–	–	﹤0.01%	819
2023 Q4	$4.21M	Buy	+91,500	New	+$3.23M	0.01%	799

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Schroder Investment Management Group's XENE Position: Q2 2026 in Review

Schroder Investment Management Group increased its Xenon Pharmaceuticals (XENE) stake by 50% in Q2 2026, buying an estimated $2.26M and bringing the position to 121,819 shares worth $7.32M. The position accounts for 0.01% of the portfolio, ranked #723.

Schroder Investment Management Group first reported a position in XENE in Q4 2023 and has held it in 11 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Schroder Investment Management Group held 121,819 shares of Xenon Pharmaceuticals worth $7.32M as of Q2 2026.
Schroder Investment Management Group bought 40,663 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.26M.
Xenon Pharmaceuticals made up 0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #723 holding.
Schroder Investment Management Group first reported a position in Xenon Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.